Drugs & TargetsFree FDA grants priority review to cemiplimab in advanced cutaneous squamous cell carcinoma May 04, 2018Vol.44 No.18
Drugs & TargetsFree Genocea files IND for neoantigen cancer vaccine candidate GEN-009 May 04, 2018Vol.44 No.18
Clinical RoundupFree Keytruda meets ORR endpoint in interim analysis of phase III trial in NSCLC May 04, 2018Vol.44 No.18
Free New data prompts CDC to examine adequacy of pre-op workup by gynecologists May 04, 2018Vol.44 No.18By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Oklahoma’s Stephenson Cancer Center earns coveted NCI Cancer Center designation May 02, 2018Vol.44 No.18By Paul Goldberg
Drugs & TargetsFree Mylotarg approved in EU for previously untreated, de novo, CD33-positive AML in combination with Chemotherapy April 27, 2018Vol.44 No.17
Drugs & TargetsFree Nektar, Takeda to evaluate combining CD122-biased agonist and dual SYK and FLT-3 inhibitor April 27, 2018Vol.44 No.17
Drugs & TargetsFree Pfizer gets Complete Response Letter for trastuzumab biosimilar April 27, 2018Vol.44 No.17
Clinical RoundupFree TESARO announces positive top-line results from Quadra trial of Zejula April 27, 2018Vol.44 No.17
FreeTrials & Tribulations Learning to “talk less and smile more” while designing a COE strategy worthy of trust April 27, 2018Vol.44 No.17By Erin N. Kobetz
